New Service for Circulating Tumor Cell Analysis Now Available
|
By LabMedica International staff writers Posted on 18 Feb 2014 |
|
Image: Fluxion’s IsoFlux system with cutting-edge technology for circulating tumor cell enrichment (Photo courtesy of Fluxion Bioscences).
A new clinical sample procurement capability, including fresh blood draws from a wide range of cancer indications and tumor subtype profiles, improves circulating tumor cell analysis services.
The cutting-edge technology of the IsoFlux system for circulating tumor cell (CTC) enrichment and analysis is among the systems from Fluxion Biosciences (South San Francisco, CA, USA) designed to replace laborious and difficult assays by providing intuitive, easy-to-use instruments for cell-based analysis. Fluxion now also has the new capability to include full-service clinical sample procurement to expand its IsoFlux Discovery Services offering. Fluxion has been providing a broad range of analytic services using its IsoFlux system for CTC enrichment, including quantitative polymerase chain reaction (qPCR) and next-generation sequencing (NGS)-based assays. With this new capability, Fluxion can now also provide clinical sample procurement that includes fresh blood draws from a wide range of cancer indications and tumor subtype profiles, such as Her2+, KRAS+, and EGFR+ samples.
The services are available to diagnostic, biopharmaceutical, and research institutes that wish to conduct CTC studies with clinical samples on a contract basis. These are provided out of Fluxion’s South San Francisco reference laboratory using cutting-edge IsoFlux technology as well as the CTC experience of Fluxion scientific personnel. With this new offering, clients can now specify the number and types of clinical samples they wish to analyze and have them included in the study without having to set up clinical agreements. The clinical samples are shipped overnight to Fluxion’s laboratory and processed the day of arrival. Each sample is highly annotated with clinical information and obtained under Institutional Review Board (IRB) consent.
“After running our Discovery Services for some time now, we realized that obtaining prospective clinical samples for CTC studies is a major bottleneck for our clients. Setting up clinical agreements, obtaining IRB approval, and waiting for patient recruitment can slow things down considerably,” said Mike Schwartz, program director at Fluxion; “This new addition to our service offering will dramatically increase the speed of discovery for our clients, not to mention make it easier to source an entire study from a single vendor.”
Related Links:
Fluxion Biosciences
Isoflux
The cutting-edge technology of the IsoFlux system for circulating tumor cell (CTC) enrichment and analysis is among the systems from Fluxion Biosciences (South San Francisco, CA, USA) designed to replace laborious and difficult assays by providing intuitive, easy-to-use instruments for cell-based analysis. Fluxion now also has the new capability to include full-service clinical sample procurement to expand its IsoFlux Discovery Services offering. Fluxion has been providing a broad range of analytic services using its IsoFlux system for CTC enrichment, including quantitative polymerase chain reaction (qPCR) and next-generation sequencing (NGS)-based assays. With this new capability, Fluxion can now also provide clinical sample procurement that includes fresh blood draws from a wide range of cancer indications and tumor subtype profiles, such as Her2+, KRAS+, and EGFR+ samples.
The services are available to diagnostic, biopharmaceutical, and research institutes that wish to conduct CTC studies with clinical samples on a contract basis. These are provided out of Fluxion’s South San Francisco reference laboratory using cutting-edge IsoFlux technology as well as the CTC experience of Fluxion scientific personnel. With this new offering, clients can now specify the number and types of clinical samples they wish to analyze and have them included in the study without having to set up clinical agreements. The clinical samples are shipped overnight to Fluxion’s laboratory and processed the day of arrival. Each sample is highly annotated with clinical information and obtained under Institutional Review Board (IRB) consent.
“After running our Discovery Services for some time now, we realized that obtaining prospective clinical samples for CTC studies is a major bottleneck for our clients. Setting up clinical agreements, obtaining IRB approval, and waiting for patient recruitment can slow things down considerably,” said Mike Schwartz, program director at Fluxion; “This new addition to our service offering will dramatically increase the speed of discovery for our clients, not to mention make it easier to source an entire study from a single vendor.”
Related Links:
Fluxion Biosciences
Isoflux
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Urine Control
MassCheck Amino Acid Analysis Urine Controls
New
RFID Tag
AD-302 M730
Latest Technology News
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
- Paper-Based Biosensor System to Detect Glucose Using Sweat Could Revolutionize Diabetes Management
- First AI-Powered Blood Test Identifies Patients in Earliest Stage of Breast Cancer
- Optical Biosensor Rapidly Detects Monkeypox Virus at Point of Care
- Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients
- New Noninvasive Methods Detect Lead Exposure Faster, Easier and More Accurately at POC
- Noninvasive Test Detects Malaria Without Blood Sample
- Low-Cost, Portable Device Detects Colorectal and Prostate Cancer in An Hour
- Light-AI Cancer Diagnosis Technology Could Eliminate Need for Traditional Blood Draws and Biopsies
Channels
Clinical Chemistry
view channel
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read more
AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
Accurately monitoring drug levels in the blood is essential for effective treatment, particularly in the management of cardiovascular diseases. Traditional techniques for monitoring blood drug levels often... Read more
Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
Timely and accurate monitoring of renal function is essential for managing patients at risk of acute kidney injury (AKI), which affects about 12% of hospitalized patients and up to 57% of ICU patients.... Read more
Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
Nanopores are tiny openings that can detect individual molecules as they pass through, making them ideal for analyzing biomolecules like DNA and proteins. However, detecting proteins at extremely low ... Read moreMolecular Diagnostics
view channel
New DNA Test Diagnoses Bacterial Infections Faster and More Accurately
Antimicrobial resistance has emerged as a significant global health threat, causing at least one million deaths annually since 1990. The Global Research on Antimicrobial Resistance (GRAM) Project warns... Read more
Innovative Bio-Detection Platform Improves Early Cancer Screening and Monitoring
Cancer remains one of the leading causes of death globally, underscoring the critical need for more advanced, efficient, and early detection methods. Circulating tumor cells (CTCs) are cells that have... Read more
Blood Test Could Help More Women Survive Aggressive Triple Negative Breast Cancer
Cancer research shows that over 90% of women diagnosed with breast cancer at its earliest stage survive for five years or more. However, this survival rate dramatically decreases to just 30% when the cancer... Read more
Hematology
view channel
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
WBC Count Could Predict Severity of COVID-19 Symptoms
The global health crisis caused by the SARS-CoV-2 virus continues to impact millions of people worldwide, with many experiencing persistent symptoms months after the initial diagnosis. Cognitive impairment... Read more
New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
Accurate platelet count testing is a significant challenge for laboratories. Inaccurate results can lead to misdiagnosis, missed diagnoses, and delayed treatment for a variety of potentially fatal conditions,... Read more
Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
Heparin-induced thrombocytopenia (HIT), a serious side effect of the blood thinner heparin, is difficult to diagnose because thrombocytopenia, or low platelet count, can be caused by a variety of factors... Read moreImmunology
view channel
Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more
Microbiology
view channel
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read more
Rapid PCR Testing in ICU Improves Antibiotic Stewardship
A collaborative study led by the University of Plymouth (Devon, UK) has shown that rapid polymerase chain reaction (PCR) testing in the intensive care unit (ICU) improved antibiotic stewardship compared... Read more
Pathology
view channel
Informatics Solution Elevates Laboratory Efficiency and Patient Care
QuidelOrtho Corporation (San Diego, CA, USA) has introduced the QuidelOrtho Results Manager System, a cutting-edge informatics solution designed to meet the increasing demands of modern laboratories.... Read more
Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread
Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
New AI Tool Outperforms Previous Methods for Identifying Colorectal Cancer from Tissue Sample Analysis
Tissue analysis typically involves a pathologist reviewing scanned digital slides from a patient’s intestinal sample and marking specific areas, such as those where cancerous and related tissues are present.... Read more
Industry
view channel
CACLP 2025 Unites Global Innovators in IVD Industry
CACLP (Shanghai, China) will be holding the 22nd China International In Vitro Diagnostic Expo, the largest and most influential gathering of the IVD industry in China, 22-24 March 2025 at the Hangzhou... Read more
Bio-Rad to Acquire Digital PCR Developer Stilla Technologies
Bio-Rad Laboratories (Hercules, CA, USA) has entered into a binding offer to purchase all equity interests in Stilla Technologies (Villejuif, France). The acquisition remains subject to consultation with... Read more
